Johnson & Johnson (NYSE:JNJ – Free Report) – Stock analysts at Cantor Fitzgerald dropped their FY2024 EPS estimates for Johnson & Johnson in a note issued to investors on Tuesday, June 25th. Cantor Fitzgerald analyst L. Chen now forecasts that the company will earn $10.47 per share for the year, down from their prior estimate of $10.57. Cantor Fitzgerald has a “Overweight” rating and a $215.00 price objective on the stock. The consensus estimate for Johnson & Johnson’s current full-year earnings is $10.63 per share.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion for the quarter, compared to analysts’ expectations of $21.39 billion. Johnson & Johnson had a net margin of 45.26% and a return on equity of 36.70%. The business’s revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.68 earnings per share.
Check Out Our Latest Stock Analysis on Johnson & Johnson
Johnson & Johnson Trading Down 0.3 %
Shares of Johnson & Johnson stock opened at $146.81 on Thursday. The company’s fifty day simple moving average is $148.13 and its 200-day simple moving average is $154.24. The stock has a market capitalization of $353.32 billion, a PE ratio of 9.15, a P/E/G ratio of 2.45 and a beta of 0.53. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94.
Institutional Investors Weigh In On Johnson & Johnson
Several large investors have recently added to or reduced their stakes in JNJ. Christopher J. Hasenberg Inc purchased a new stake in Johnson & Johnson in the 1st quarter valued at about $31,000. Keener Financial Planning LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $40,000. WFA Asset Management Corp boosted its position in Johnson & Johnson by 61.4% in the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares during the period. Vermillion & White Wealth Management Group LLC purchased a new stake in Johnson & Johnson in the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. purchased a new stake in shares of Johnson & Johnson in the 4th quarter worth approximately $45,000. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Increases Dividend
The company also recently declared a quarterly dividend, which was paid on Tuesday, June 4th. Investors of record on Tuesday, May 21st were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.38%. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.19. The ex-dividend date of this dividend was Monday, May 20th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
Read More
- Five stocks we like better than Johnson & Johnson
- 10 Best Airline Stocks to Buy
- Why Paychex Stock’s Dip is the Best Opportunity in Today’s Cycle
- What is a buyback in stocks? A comprehensive guide for investors
- Any Pullback in Tech May Signal a Rotation into These 3 Sectors
- Technology Stocks Explained: Here’s What to Know About Tech
- 3 Stocks to Watch: Oracle, Casey’s, FedEx Signal Big Gains
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.